

A microscopic view of cells, likely skin cells, showing various shapes and structures. The cells are rendered in shades of green and blue, with some appearing more rounded and others more elongated. The background is a dark, almost black, color, making the cells stand out.

A logo consisting of a white sunburst or starburst shape with multiple rays emanating from a central point.

NUTRIKOSM

NK CELL


WITH OVODERM, VITIS VINIFERA, GINGKO BILOBA, CENTELLA ASIÁTICA

WHAT IS CELLULITE?


Cellulite is a skin disorder that is often described as the appearance of “orange peel” or “dimples” in the thighs, buttocks, and sometimes in the lower abdomen and upper extremities, women’s arms. *About 85% of postpartum women have some form of cellulite.* Although rarely seen in men, those with cellulite are commonly deficient in male hormones.

To better understand what cellulite is, a review of the microanatomy of the skin is needed: the outermost layer of the skin is called the **epidermis**. Immediately below this is the **dermis** (also called the *chorion*), which is richly filled with *hair follicles, sweat glands, blood vessels, nerve receptors and connective tissue*. The next layer of tissue is the first of two layers of subcutaneous fat.

The main evidence available today shows that cellulite is found in this first layer of subcutaneous fat, called the areolar layer, with chambers of fat cells -or lobes- arranged vertically. According to this scientific explanation, cellulite is caused by these small fat cells (papillae adiposae) in the dermis. This structural alteration of the subcutaneous fat that protrudes (or is herniated) in the dermis gives the skin the “rough” appearance known as cellulite.



NORMAL SKIN



SKIN AFFECTED BY CELLULITE

HOW IS IT CLASSIFIED?

There are 4 types of cellulite::

- **Hard:** Firm toned tissue, hard to the touch. Typically found in young women who do physical exercise. It is usually associated with stretch marks and corresponds to grade II.
- **Soft or Flaccid:** The tissues are soft and sway with movement. In inactive women and in those who have lost weight suddenly.
- **Oedematous:** It is the most severe and least frequent. It is accompanied by swelling of the lower limbs and occasional pain.
- **Mixed:** This is the most frequently found, where more than one type of cellulite is found at different sites on the same person.

They are classified as follows:

Grade I: Practically invisible, you have to squeeze the area hard to see the dimples.

Grade II: Cellulite is visible at a glance if you squeeze the affected area.

Grade III: You don't have to squeeze the area. You can see the cellulite when standing still in front of a mirror. However, if you are lying down and are not squeezing the area, you can't see it.

Grade IV: This is the most serious type, sometimes painful, and always accompanied by excessive fluid retention and swelling. Cellulite is even visible when you are lying down without contracting the muscles or squeezing the area.




¿WHY TAKE **NK CELL**?

NK CELL is a nutri-cosmetic that helps reduce and soften “orange peel skin”. It contains a number of ingredients, including **vitis vinifera**, which helps reduce cellulite, and **OVODERM®**, which plays a role in cell growth and the maintenance of vital functions. It also contains **Centella Asiatica** (Asian Pennywort), which prevents damage through oxidation and improves circulation, and **Ginkgo Biloba**, which helps improve circulation by expanding the microcapillaries and reinforcing the walls of the blood vessels, making it an ideal component to stimulate localised lipolysis and to treat cellulite.

OVODERM® is an egg membrane extract that naturally contains nutrients such as proteins, glycosaminoglycans and peptides that help maintain connective tissues and thus help improve skin health and condition.

La **Centella Asiática** or Asian Pennywort is a plant found mainly in India, China, Indonesia, South Africa and Madagascar. It has healing, anti-inflammatory, re-structuring and venoprotective properties. It is often used in dermatology to promote healing and regenerate the skin. Centella Asiatica extracts have been shown to stimulate collagen biosynthesis and therefore improve the firmness and elasticity of the skin.



SOURCE OF EGG
MEMBRANE EXTRACT
FOR THE OVODERM®
COMPONENT.



GOTU KOLA (CENTELLA ASIÁTICA)


SCIENTIFIC PRINCIPLES



The tool routinely used to measure skin barrier function is transepidermal water loss (TEWL), which is the normal permeability of water through the stratum corneum (SC) to the atmosphere.

EFFECT OF DAILY USE OF OVODERM® ON THE HYDRATION, ELASTICITY, FIRMNESS AND FATIGUE OF THE SKIN

$P \leq 0.05$
compared to
the baseline



A single-center, double-blind, randomized clinical-nutritional study was conducted to evaluate the efficacy of daily intake of **NK Cell** containing 300 mg of Ovoderm ©. The study was carried out on 16 volunteers between 45 and 75 years old, who were randomly assigned to one of two groups: 7 to Ovoderm © and 9 to Placebo.

After 60 days of treatment, the **NK Cell** group showed a significant reduction in the result from 0.656 on day 0 to 0.569 on day 60. This represents a 13.3% improvement in skin elasticity with our product, compared to an 11.3% reduction in the placebo group after 60 days of treatment.

The ingestion of the **NK Cell** showed a statistically significant change from 0.264 mm on day 0 to 0.09 mm on day 60, while no significant changes were shown in the Placebo group. The former improved skin firmness by 65.8%, while the other improved only 44.6%.

There was also a statistically significant improvement in the reduction of skin fatigue. Showing 0.031 mm on day 0 and 0.021 mm on day 60 in the **NK Cell** group, which represents 35.62%, while the other group did not show statistically significant differences.

SCIENTIFIC PRINCIPLES

Several studies carried out on grape seed extract, which contains monomeric and oligomeric flavanols, yielded positive results in protecting capillaries and their fragility.

EFFECTS OF SEED EXTRACT GRAPE IN HUMAN HEALTH

An open study conducted on 46 subjects with a 100-150 mg daily dose of grape seed extract for 30-45 days reported a reduction in **capillary fragility** in 39 of the 46 subjects evaluated via the suction method.

To confirm these findings, the researchers performed a second study that was placebo-controlled: daily intake of the preparation of Masquelier grape seeds over 15 days improved capillary fragility in 10 out of 21 patients, while in the placebo group a similar effect was observed in just 3 of the 12 subjects.

Capillary resistance, defined as the properties of the capillaries to counteract the forces of rupture, improved with the intake of 100-150 mg after 15-30 days of intervention.

Capillary resistance protection was also demon-

strated in a controlled double-blind study with placebo in subjects with either capillary fragility or acetylsalicylic acid-induced capillary fragility.

In a double-blind, placebo-controlled trial, skin temperature measurement was used as a measure of dermal circulation and geographic parameters, to demonstrate **improved venous tone** in subjects who took 150 mg of Masquelier preparation daily for 45 days.

A study was also conducted on 78 patients with a variety of problems related to capillary fragility, taking 150 mg of grape seed extract for 15-90 days, and a reduction in fragility was observed in 62 of the 78 subjects.

Conclusion

The numerous human intervention studies that became available over time provided the basis for designing an intervention study that employed innovative biomolecular techniques and reflected conceptual advances in nutritional science. This novel approach enabled researchers to capture the pleiotropic effects of Masquelier grape seed extract on vascular health in humans. This physiological benefit can be summarised as “maintenance of vascular homeostasis”.

NK CELL AT A GLANCE

- ▶ Combats capillary fragility and improves strength
 - ▶ Improves cardiovascular health and prevents diseases
 - ▶ Not genetically modified
 - ▶ Gluten-free
 - ▶ Approved as a food supplement in Europe and the United States
-





NK Cell is a nutri-cosmetic that helps reduce and soften “orange peel skin”. It contains many components, including vitis vinifera, which helps reduce cellulite and aids slimming, OVODERM®, an extract of egg membrane that naturally contains nutrients such as proteins, glycosaminoglycans and peptides that help maintain connective tissues and also play a role in cell growth and the maintenance of vital functions. It also contains Centella asiatica, Vitamin C, and Ginkgo Biloba, which prevent oxidation damage and improve circulation, and also increase the oxidation of fats.

INGREDIENTS

L-CARNITINE TARTRATE 68%
 VITIS VINIFERA 5%
 OVODERM®
 CENTELLA ASIÁTICA 10%
 VITAMINE C
 NATURAL CAFFEINE
 GINGKO BILOBA

PER CAPSULE MG

250
 175
 150
 50
 50
 50
 25

VRN*% MG ACTIVE/DOSAGE (2 CAPSULES)

125% (100 MG VIT C)

NK CELL



PACKAGING

Primary: Bottle containing 60 capsules
Secondary: Cardboard box with cellophane wrap.

ACTIVE INGREDIENTS

Vitis vinífera, OVODERM®, Gingko Biloba, Centella Asiática.

ALLERGENS

Contains egg.

INGREDIENTS

L-carnitine, red grape, OVODERM®, Centella Asiatica, Diosmin, Vitamin C, Natural Caffeine, Gingko Biloba, magnesium stratum, silicon dioxide.





NKCELL

REJUVENATE YOUR SKIN
FROM THE INSIDE FOR VISIBLE
RESULTS ON THE OUTSIDE.

References

1. Nassiri-Asi M, Hosseinzadeh H. Review of the pharmacological effects of *Vitis vinifera* (grape) and its bioactive constituents: an update. *Phytother Res*. 2016;30(9):1392-403.
2. Olaku OO, Ojukwu MO, Zia FZ, White JD. The role of grape seed extract in the treatment of chemo/radiotherapy induced toxicity: a systematic review of preclinical studies. *Nutr Cancer*. 2015;67:730-40.
3. Kasdagly M, Radhakrishnan S, Reddivari L, Veeramachaneni DN, Vanamala J. Colon carcinogenesis: influence of Western diet-induced obesity and targeting stem cells using dietary bioactive compounds. *Nutrition*. 2014;30:1242-56.
4. Ting H, Deep G, Agarwal C, Agarwal R. The strategies to control prostate cancer by chemoprevention approaches. *Mutat Res*. 2014;760:1-15.
5. Tong LX, Young LC. Nutrition: the future of melanoma prevention? *J Am Acad Dermatol*. 2014;71:151-60.
6. Feringa HH, Laskey DA, Dickson JE, Coleman CI. The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials. *J Am Diet Assoc*. 2011;111:1173-81.
7. Ho L, Pasinetti GM. Polyphenolic compounds for treating neurodegenerative disorders involving protein misfolding. *Expert Rev Proteomics*. 2010;7:579-89.
8. Pasinetti GM, Ho L. Role of grape seed polyphenols in Alzheimer's disease neuropathology. *Nutr Diet Suppl*. 2010;2010:97-103.
9. Wu CD. Grape products and oral health. *J Nutr*. 2009;139:1818S-23S.
10. Baumann LS. Less-known botanical cosmeceuticals. *Dermatol Ther*. 2007;20: 330-42.
11. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, Capella D, Bonfill Cosp X. Phlebotonics for venous insufficiency. *Cochrane Database Syst Rev*. 2016;4:CD003229.
12. World Health Organization (WHO). Constitution of the World Health Organization - basic documents, vol. Supplement. 45th ed. 2006.
13. Michaud JMJRAM. Synthèse des procyanidines naturelles. *Ann Pharm Fr*. 1973;31:385-95.
14. Dewick PM. The Shikimate Pathway: Aromatic Amino Acids and Phenylpropanoids. In: *Medicinal Natural Products*. Hoboken: Wiley; 2009. p. 137-86.
15. Xie D-Y, Dixon RA. Proanthocyanidin biosynthesis - still more questions than answers? *Phytochemistry*. 2005;66:2127-44.

16. He F, Pan QH, Shi Y, Duan CQ. Biosynthesis and genetic regulation of proanthocyanidins in plants. *Molecules*. 2008;13:2674–703.
17. Dixon RA, Xie D-Y, Sharma SB. Proanthocyanidins – a final frontier in flavonoid research? *New Phytol*. 2005;165:9–28.
18. Vaughn KC, Lax AR, Duke SO. Polyphenol oxidase: The chloroplast oxidase with no established function. *Physiol Plant*. 1988;72:659–65.
19. Creasy LL, Swain T. Structure of condensed tannins. *Nature*. 1965;208:151–3.
20. Baxter IR, Young JC, Armstrong C, Foster N, Bogenschütz N, Cordova T, Peer WA, Hazen SP, Murphy AS, Harper JF. A plasma membrane H⁺-ATPase is required for the formation of proanthocyanidins in the seed coat endothelium of *Arabidopsis thaliana*. *Proc Natl Acad Sci U S A*. 2005;102: 2649–54.
21. Hemingway RW, Foo LY, Porter LJ. Linkage isomerism in trimeric and polymeric 2,3-cis-procyanidins. *J Chem Soc, Perkin Trans*. 1982;1:1209–16.
22. St Leger AS, Cochrane AL, Moore F. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. *Lancet*. 1979;1:1017–20.
23. Prior RL, Gu L. Occurrence and biological significance of proanthocyanidins in the American diet. *Phytochemistry*. 2005;66:2264–80.
24. USDA database for the proanthocyanidin content of selected foods - 2004, available at <https://www.ars.usda.gov/northeast-area/beltsville-md/beltsville-human-nutrition-research-center/nutrient-data-laboratory/docs/usda-database-for-the-proanthocyanidin-content-of-selected-foods-2004/> accessed. Accessed 30 June 2016.
25. Gu L, Kelm MA, Hammerstone JF, Beecher G, Holden J, Haytowitz D, Gebhardt S, Prior RL. Concentrations of proanthocyanidins in common foods and estimations of normal consumption. *J Nutr*. 2004;134:613–7.
26. Zamora-Ros R, Knaze V, Hémon B, Moskal A, Overvad K, Tjønneland A, Kyø C, Fagherazzi G, Boutron-Ruault M-C, et al. Dietary polyphenol intake in Europe: the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Eur J Nutr*. 2015;55:1–17.
27. Vogiatzoglou A, Mulligan AA, Luben RN, Lentjes MAH, Heiss C, Kelm M, Merx MW, Spencer JPE, Schroeter H, Kuhnle GGC. Assessment of the dietary intake of total flavan-3-ols, monomeric flavan-3-ols, proanthocyanidins and theaflavins in the European Union. *Br J Nutr*. 2014;111:1463–73.
28. Knaze V, Zamora-Ros R, Lujan-Barroso L, Romieu I, Scalbert A, Slimani N, Riboli E, van Rossum CT, Bueno-de-Mesquita HB, Trichopoulou A, et al. Intake estimation of total and individual flavan-3-ols, proanthocyanidins and theaflavins, their food sources and determinants in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Br J Nutr*. 2012;108:1095–108.
29. Sebastian RS, Wilkinson Enns C, Goldman JD, Martin CL, Steinfeldt LC, Murayi T, Moshfegh AJ. A New database facilitates characterization of flavonoid intake, sources, and positive associations with diet quality among US adults. *J Nutr*. 2015;145:1239–48.
30. Wang Y, Chung S-J, Song WO, Chun OK. Estimation of daily proanthocyanidin intake and major food sources in the U.S. diet. *J Nutr*. 2011;141:447–52.
31. Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. *Nutr Cancer*. 2006;55:1–12.
32. Chan SC, Ho SC, Kreiger N, Darlington G, Adlaf EM, So KF, Chong PY. Validation of a food frequency questionnaire for assessing dietary soy isoflavone intake among midlife Chinese women in Hong Kong. *J Nutr*. 2008;138:567–73.
33. Chan SC, Ho SC, Kreiger N, Darlington G, So KF, Chong PY. Dietary sources and determinants of soy isoflavone intake among midlife Chinese Women in Hong Kong. *J Nutr*. 2007;137:2451–5.
34. Kim J-S, Kwon C-S. Estimated dietary isoflavone intake of Korean population based on National Nutrition Survey. *Nutr Res*. 2001;21:947–53.
35. Li G, Zhu Y, Zhang Y, Lang J, Chen Y, Ling W. Estimated daily flavonoid and stilbene intake from fruits, vegetables, and nuts and associations with lipid profiles in Chinese adults. *J Acad Nutr Diet*. 2013;113:786–94.
36. Woo H, Lee J, Choi I, Kim C, Lee J, Kwon O, Kim J. Dietary flavonoids and gastric cancer risk in a Korean population. *Nutrients*. 2014;6:4961–73.
37. Otaki N, Kimira M, Katsumata S-i, Uehara M, Watanabe S, Suzuki K. Distribution and major sources of flavonoid intakes in the middle-aged Japanese women. *J Clin Biochem Nutr*. 2009;44:231–8.
38. Johannot L, Somers SM. Age-related variations in flavonoid intake and sources in the Australian population. *Public Health Nutr*. 2006;9:1045–54.
39. Ivey KL, Lewis JR, Lim WH, Lim EM, Hodgson JM, Prince RL. Associations of proanthocyanidin intake with renal function and clinical outcomes in elderly women. *PLoS One*. 2013;8:e71166.
40. Arabbi PR, Genovese MI, Lajolo FM. Flavonoids in vegetable foods commonly consumed in Brazil and estimated ingestion by the Brazilian Population. *J Agric Food Chem*. 2004;52:1124–31.
41. Corrêa VG, Tureck C, Locatelli G, Peralta RM, Koehnlein EA. Estimate of consumption of phenolic compounds by Brazilian population. *Rev Nutr*. 2015;28:185–96.
42. Neveu V, Perez-Jiménez J, Vos F, Crespy V, du Chaffaut L, Mennen L, Knox C, Eisner R, Cruz J, Wishart D, Scalbert A. Phenol-Explorer: an online comprehensive database on polyphenol contents in foods. *Database (Oxford)*. 2010;2010:bap024.
43. World Health Organization (WHO). Diet, nutrition and the prevention of chronic diseases In: WHO Tech Rep Ser, vol. No. 916 (TRS 916). Geneva: WHO; 2003.
44. Bauer R. Quality criteria and standardization of phytopharmaceuticals: Can acceptable drug standards be achieved? *Drug Inf J*. 1998;32:101–10.
45. Singleton VL, Rossi JA. Colorimetry of total phenolics with phosphomolybdic- phosphotungstic acid reagents. *Am J Enol Vitic*. 1965;16:144–58.
46. Stalikas CD. Extraction, separation, and detection methods for phenolic acids and flavonoids. *J Sep Sci*. 2007;30:3268–95.
47. Bate-Smith EC. Phytochemistry of proanthocyanidins. *Phytochemistry*. 1975; 14:1107–13.
48. Porter LJ, Hrstich LN, Chan BC. The conversion of procyanidins and prodelphinidins to cyanidin and delphinidin. *Phytochemistry*. 1985;25:223–30.
49. Schofield P, Mbugua DM, Pell AN. Analysis of condensed tannins: a review. *Anim Feed Sci Technol*. 2001;91:21–40.
49. Sun B, Ricardo-da-Silva JM, Spranger I. Critical factors of vanillin assay for catechins and proanthocyanidins. *J Agric Food Chem*. 1998;46:4267–74.
51. Naczki M, Shahidi F. Phenolics in cereals, fruits and vegetables: occurrence, extraction and analysis. *J Pharm Biomed Anal*. 2006;41:1523–42.
52. Ignat I, Volf I, Popa VI. A critical review of methods for characterisation of polyphenolic compounds in fruits and vegetables. *Food Chem*. 2011;126:1821–35.
53. Khoddami A, Wilkes MA, Roberts TH. Techniques for analysis of plant phenolic compounds. *Molecules*. 2013;18:2328–75.
50. Dumon M, Michaud J, Masquelier J. Dosages des procyanidols dans les extraits végétaux destinés à la préparation de médicaments. *Bull Soc Pharm Bord*. 1990;129:51–65.
51. Dumon M. Recherches analytiques sur les pycnogenols. PhD thesis. Bordeaux: Université de Bordeaux II, UFR des Sciences Pharmaceutiques; 1990.
56. de Haan B, Achanta G, Post JA. A potential role for oligomeric proanthocyanidins (OPCs) in delaying senescence in human endothelial cells. *Free Radic Biol Med*. 2008;45:S78.
52. Krishnan P, Kruger NJ, Ratcliffe RG. Metabolite fingerprinting and profiling in plants using NMR. *J Exp Bot*. 2005;56:255–65.
53. Hylands PJN, JK, Holmes E, Dunn MJ. Process for quality control and standardization of medicinal plant products. In Google patent, vol. US6806090 B1. USA; 2004.
54. Laparra J, Michaud J, Masquelier J. Étude pharmacocinétique des oligomères flavanoliques. *Plantes Médicinales Phytothérapie*. 1977;9:133–42.
60. Laparra J, Michaud J, Lesca MF, Blanquet P, Masquelier J. Étude pharmacocinétique des oligomères procyanidoliques totaux du raisin. *Acta Ther*. 1978;4:233–46.
55. Jacobs H, Koek GH, Peters R, Moalin M, Tack J, van der Vijgh WJ, Bast A, Haenen GR. Differences in pharmacological activities of the antioxidant flavonoid monohesperidin in humans and mice are caused by variations in its metabolic profile. *Clin Pharmacol Ther*. 2011;90:852–9.
56. Benakis A, Schopfer C, Ritschard J. Disposition of ¹⁴C-labelled ENDOTELON in humans. *Eur J Drug Metab Pharmacokinet*. 2008;33:37–43.
57. Choy YY, Jaggars GK, Oteiza PI, Waterhouse AL. Bioavailability of intact proanthocyanidins in the rat colon after ingestion of grape seed extract. *J Agric Food Chem*. 2013;61:121–7.
58. Prasain JK, Peng N, Dai Y, Moore R, Arabshahi A, Wilson L, Barnes S, Michael Wyss J, Kim H, Watts RL. Liquid chromatography tandem mass spectrometry identification of proanthocyanidins in rat plasma after oral ad-

ministration of grape seed extract. *Phytomedicine*. 2009;16:233-43.

59. Serra A, Macia A, Romero MP, Salvado MJ, Bustos M, Fernandez-Larrea J, Motilva MJ. Determination of procyanidins and their metabolites in plasma samples by improved liquid chromatography-tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2009;877:1169-76.
60. Tsang C, Auger C, Mullen W, Bornet A, Rouanet JM, Crozier A, Teissedre PL. The absorption, metabolism and excretion of flavan-3-ols and procyanidins following the ingestion of a grape seed extract by rats. *Br J Nutr*. 2005;94:170-81.
61. Actis-Goretta L, Leveques A, Rein M, Teml A, Schafer C, Hofmann U, Li H, Schwab M, Eichelbaum M, Williamson G. Intestinal absorption, metabolism, and excretion of (-)-epicatechin in healthy humans assessed by using an intestinal perfusion technique. *Am J Clin Nutr*. 2013;98:924-33.
62. Ottaviani JI, Momma TY, Kuhnle GK, Keen CL, Schroeter H. Structurally related (-)-epicatechin metabolites in humans: Assessment using de novo chemically synthesized authentic standards. *Free Radic Biol Med*. 2012;52:1403-12.
63. Holt RR, Lazarus SA, Sullards MC, Zhu QY, Schramm DD, Hammerstone JF, Fraga CG, Schmitz HH, Keen CL. Procyanidin dimer B2 [epicatechin-(4 β)-epicatechin] in human plasma after the consumption of a flavanol-rich cocoa. *Am J Clin Nutr*. 2002;76:798-804.
64. Sano A, Yamakoshi J, Tokutake S, Tobe K, Kubota Y, Kikuchi M. Procyanidin B1 is detected in human serum after intake of proanthocyanidin-rich grape seed extract. *Biosci Biotechnol Biochem*. 2003;67:1140-3.
65. Deprez S, Mila I, Huneau JF, Tome D, Scalbert A. Transport of proanthocyanidin dimer, trimer, and polymer across monolayers of human intestinal epithelial Caco-2 cells. *Antioxid Redox Signal*. 2001;3:957-67.
66. Rios LY, Gonthier M-P, Révész C, Mila I, Lapiere C, Lazarus SA, Williamson G, Scalbert A. Chocolate intake increases urinary excretion of polyphenol-derived phenolic acids in healthy human subjects. *Am J Clin Nutr*. 2003;77:912-8.
67. Appeldoorn MM, Vincken JP, Aura AM, Hollman PC, Gruppen H. Procyanidin dimers are metabolized by human microbiota with 2-(3,4-dihydroxyphenyl)acetic acid and 5-(3,4-dihydroxyphenyl)-gamma-valerolactone as the major metabolites. *J Agric Food Chem*. 2009;57:1084-92.
68. Stoupi S, Williamson G, Drynan JW, Barron D, Clifford MN. Procyanidin B2 catabolism by human fecal microflora: Partial characterization of 'dimeric' intermediates. *Arch Biochem Biophys*. 2010;501:73-8.
69. Wiese S, Esatbeyoglu T, Winterhalter P, Kruse H-P, Winkler S, Bub A, Kulling SE. Comparative biokinetics and metabolism of pure monomeric, dimeric, and polymeric flavan-3-ols: A randomized cross-over study in humans. *Mol Nutr Food Res*. 2015;59:610-21.
70. Nakamura Y, Tsuji S, Tonogai Y. Analysis of proanthocyanidins in grape seed extracts, health foods and grape seed oils. *J Health Sci*. 2003;49:45-54.
71. Masquelier J, Dumon M, Dumas J. Stabilisation du collagène par les oligomères procyanidoliques. *Acta Ther*. 1981;7:101-5.
72. Pfister A, Simon M, Gazave J. Sites de fixation des oligomères procyanidoliques dans la paroi des capillaires sanguins du poulmon de cobaye. *Acta Ther*. 1982;8:223-37.
73. Tixier JM, Godeau C, Robert AM, Hornebeck W. Evidence by in vivo and in vitro studies that binding of pycnogenols to elastin affects its rate of degradation by elastases. *Biochem Pharmacol*. 1984;33:3933-9.
74. Gavignet-Jeannin C, Groult N, Godeau G, Robert A, Robert L. Mode d'action des oligomères procyanidoliques sur la paroi vasculaire. Toulouse: Congrès International d'Angiologie, symposium satellite Endotelon et unite circulatoire; 1988.
75. Robert AM. Substrate-protecting antiproteolytic agents for the prevention of pathological degradation of connective tissues. A review. *Pathol Biol (Paris)*. 2012;60:48-57.
76. Oligomeric proanthocyanidins (OPCs). Monograph *Altern Med Rev* 2003, 8:442-450.
77. Bast A, Haenen GRMM. Ten misconceptions about antioxidants. *Trends Pharmacol Sci*. 2013;34:430-6.
78. Weseler AR, Bast A. Oxidative stress and vascular function: implications for pharmacologic treatments. *Curr Hypertens Rep*. 2010;12:154-61.
79. Masquelier J. Action comparee de divers facteurs vitaminiques P sur l'oxydation de l'acide ascorbique par les ions cuivriques. *Bull Soc Chim Biol (Paris)*. 1951;33:302-5.
80. Masquelier J. Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof, vol. US4698360 A. USA; 1987.
81. van Acker SA, de Groot MJ, van den Berg DJ, Tromp MN, Donne-Op den Kelder G, van der Vijgh WJ, Bast A. A quantum chemical explanation of the antioxidant activity of flavonoids. *Chem Res Toxicol*. 1996;9:1305-12.
82. Barbier AM, JP, Savi P, Unkovic J, Vilain P. Activite angioprotectrice des oligomères procyanidoliques chez l'animal. Toulouse: Congrès International d'Angiologie; 1988.
83. Meunier M, Duroux E, Bastide P. Activite antiradicalaire d'oligomères procyanidolique et d'anthocyanosides vis-a-vis de l'anion superoxyde et vis-a-vis de la lipoperoxydation. *Plantes Medicinales Phytotherapie*. 1989;13:267-74.
84. Masquelier J. Effets physiologiques du vin - Sa part dans l'alcoolisme. *Bulletin de l'OIV*. 1988;689:555-78.
85. de Haan B, Babat S, Post JA. Protection of vascular endothelial cells from oxidative damage by oligomeric proanthocyanidins. In: *Oxidants and antioxidants in biology*. Santa Barbara: Oxygen Club of California; 2006.
86. de Haan B, Babat S, Post JA. Oligomeric proanthocyanidins protect vascular endothelial cells from lipid oxidation. *Inflamm Res*. 2006;Supplement 2:S116.
87. Bos MA, Vennat B, Meunier MT, Pouget MP, Pourrat A, Fialip J. Procyanidins from tormentil: antioxidant properties towards lipoperoxidation and anti-elastase activity. *Biol Pharm Bull*. 1996;19:146-8.
88. Ruijters EJ, Weseler AR, Kicken C, Haenen GR, Bast A. The flavanol (-)-epicatechin and its metabolites protect against oxidative stress in primary endothelial cells via a direct antioxidant effect. *Eur J Pharmacol*. 2013;715:147-53.
89. Granado-Serrano AB, Martin MA, Haegeman G, Goya L, Bravo L, Ramos S. Epicatechin induces NF-kappaB, activator protein-1 (AP-1) and nuclear transcription factor erythroid 2p45-related factor-2 (Nrf2) via phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) and extracellular regulated kinase (ERK) signalling in HepG2 cells. *Br J Nutr*. 2010;103:168-79.
90. Rodriguez-Ramiro I, Ramos S, Bravo L, Goya L, Martin MA. Procyanidin B2 induces Nrf2 translocation and glutathione S-transferase P1 expression via ERKs and p38-MAPK pathways and protect human colonic cells against oxidative stress. *Eur J Nutr*. 2012;51:881-92.
91. Ohnuma T, Anzai E, Suzuki Y, Shimoda M, Saito S, Nishiyama T, Ogura K, Hiratsuka A. Selective antagonization of activated Nrf2 and inhibition of cancer cell proliferation by procyanidins from Cinnamomi Cortex extract. *Arch Biochem Biophys*. 2015;585:17-24.
92. Krajka-Kuzniak V, Paluszczak J, Oszmianski J, Baer-Dubowska W. Hawthorn (*Crataegus oxyacantha* L.) bark extract regulates antioxidant response element (ARE)-mediated enzyme expression via Nrf2 pathway activation in normal hepatocyte cell line. *Phytother Res*. 2014;28:593-602.
93. Bak MJ, Jun M, Jeong WS. Procyanidins from wild grape (*Vitis amurensis*) seeds regulate ARE-mediated enzyme expression via Nrf2 coupled with p38 and PI3K/Akt pathway in HepG2 cells. *Int J Mol Sci*. 2012;13:801-18.
94. Nazimabashir, Manoharan V, Miltonprabu S. Cadmium induced cardiac oxidative stress in rats and its attenuation by GSP through the activation of Nrf2 signaling pathway. *Chem Biol Interact*. 2015;242:179-93.
95. Chen S, Zhu Y, Liu Z, Gao Z, Li B, Zhang D, Zhang Z, Jiang X, Liu Z, Meng L, et al. Grape seed proanthocyanidin extract ameliorates diabetic bladder dysfunction via the activation of the Nrf2 pathway. *PLoS One*. 2015;10:e0126457.
96. Blazso G, Gabor M. Oedema-inhibiting effect of procyanidin. *Acta Physiol Acad Sci Hung*. 1980;56:235-40.
97. Li Q, Verma IM. NF-kappaB regulation in the immune system. *Nat Rev Immunol*. 2002;2:725-34.
98. Milenkovic D, Vanden Berghe W, Boby C, Leroux C, Declercq K, Szarc vel Szc K, Heyninck K, Laukens K, Bizet M, Defrance M, et al. Dietary flavanols modulate the transcription of genes associated with cardiovascular pathology without changes in their DNA methylation state. *PLoS One*. 2014;9:e95527.
99. Ruijters EJ, Haenen GR, Weseler AR, Bast A. The cocoa flavanol (-)-epicatechin protects the cortisol response. *Pharmacol Res*. 2014;79:28-33.
100. Ruijters EJ, Haenen GR, Willemsen M, Weseler AR, Bast A. Food-derived bioactives can protect the anti-inflammatory activity of cortisol with antioxidant-dependent and -independent mechanisms. *Int J Mol Sci*.

2016;17:239–48.

101. Weseler AR, Bast A. Pleiotropic-acting nutrients require integrative investigational approaches: the example of flavonoids. *J Agric Food Chem*. 2012;60:8941-6.
102. Dartenuc J, Marache P, Choussat H. Resistance capillaire en geriatrie: etude d'un microangioprotecteur endotelon. *Bordeaux Med*. 1980;13:903-7.
103. Dubos C, Durst G, Hugonot R. Evolution de la resistance capillaire, spontanement ou artificiellement diminuee par l'action d'un substance capillaro-toxique chez des personnes agees. *Revue Geriatr*. 1980;5:302-5.
104. Paitel D. Etude rheographique et thermographique des effets d'un endotheliotrophique sur l'hemodynamique peripherique. *Vie Med*. 1981;11:776-83.
105. Beylot C, Bioulac P. Essai therapeutique d'un angioprotecteur peripherique, l'Endotelon. *Gaz Med (Paris)*. 1980;87:2919-22.
106. Elbaz C, Reinharez D, Sapin G, Brami C, Boschet P, Counon P, Roure M, Tragit R, Vergoz L. Etude multicentrique controlee de l'endotelon dans les manifestations fonctionelles de l'insufficance veineuse chronique des membres inferieurs. *Le Praticien*. 1981;400:63-8.
107. Thebaut J-F, Thebaut P, Vin F. Etude de l'endotelon dans les manifestations fonctionelles de l'insufficance veineuse peripherique. Resultats d'une etude en double aveugle portant sur 92 patients. *Gaz Med (Paris)*. 1985;92:96-100.
108. Weseler AR, Ruijters EJ, Drijtj-Reijnders MJ, Reesink KD, Haenen GR, Bast A. Pleiotropic benefit of monomeric and oligomeric flavanols on vascular health - a randomized controlled clinical pilot study. *PLoS One*. 2011;6:e28460.
109. Aragonés G, Suarez M, Ardid-Ruiz A, Vinaixa M, Rodríguez MA, Correig X, Arola L, Blade C. Dietary proanthocyanidins boost hepatic NAD(+) metabolism and SIRT1 expression and activity in a dose-dependent manner in healthy rats. *Sci Rep*. 2016;6:24977.
110. NHS Digital. Hospital Episode Statistics for England 2014–15 <https://digital.nhs.uk/catalogue/PUB19124> [Accessed 9 April 2017].
111. Bennett JE, Dolin R, Blaser MJ, Mandell GL. Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th edn. Philadelphia: Churchill Livingstone/Elsevier, 2010.
112. Eron LJ, Lipsky BA. Use of cultures in cellulitis: when, how, and why? *Eur J Clin Microbiol Infect Dis* 2006;25:615-17.
113. Bläckberg A, Trell K, Rasmussen M. Erysipelas, a large retrospective study of aetiology and clinical presentation. *BMC Infect Dis* 2015;15:402.
114. Eriksson B, Jorup-Rönström C, Kärkkonen K, Sjöblom AC, Holm SE. Erysipelas: clinical and bacteriologic spectrum and serological aspects. *Clin Infect Dis* 1996;23:1091-8.
115. Chambers HF. Cellulitis, by any other name. *Clin Infect Dis* 2013;56:1763-4.
116. Borschitz T, Schlicht S, Siegel E, Hanke E, von Stebut E. Improvement of a clinical score for necrotizing fasciitis: 'Pain out of proportion' and high CRP levels aid the diagnosis. *PLoS One* 2015;10:e0132775.
117. Keller EC, Tomecki KJ, Alraies MC. Distinguishing cellulitis from its mimics. *Cleve Clin J Med*. 2012;79:547-52.
118. Dupuy A, Benchikhi H, Roujeau JC et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. *BMJ* 1999;318:1591-4.
119. Björnsdóttir S, Gottfredsson M, Thórisdóttir AS et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. *Clin Infect Dis* 2005;41:1416-22.
120. Semel JD, Goldin H. Association of athlete's foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsi-lateral interdigital space samples. *Clin Infect Dis* 1996;23:1162-4.
121. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2014;59:e10-52.
122. Weng QY, Raff AB, Cohen JM et al. Costs and consequences associated with misdiagnosed lower extremity cellulitis. *JAMA Dermatol* 2017;153:141-6.
123. Levell NJ, Wingfield CG, Garioch JJ. Severe lower limb cellulitis is best diagnosed by dermatologists and managed with shared care between primary and secondary care. *Br J Dermatol* 2011;164:1326-8.
124. Eron LJ, Lipsky BA, Low DE et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. *J Antimicrob Chemother* 2003;52(Suppl 1):i3-17.
125. Fulton R, Doherty L, Gill D et al. Guidelines on the management of cellulitis in adults. Northern Ireland: CREST, 2005.
126. Marwick C, Broomhall J, McCowan C et al. Severity assessment of skin and soft tissue infections: cohort study of management and outcomes for hospitalized patients. *J Antimicrob Chemother* 2011;66:387-97.
127. Raff AB, Weng QY, Cohen JM et al. A predictive model for diagnosis of lower extremity cellulitis: A cross-sectional study. *J Am Acad Dermatol* 2017;76:618-25.
128. National Institute for Health and Care Excellence. Sepsis: recognition, diagnosis and early management. London: NICE, 2016.
129. Pallin DJ, Binder WD, Allen MB et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. *Clin Infect Dis* 2013;56:1754-62.
130. Leman P, Mukherjee D. Flucloxacillin alone or combined with benzylpenicillin to treat lower limb cellulitis: a randomised controlled trial. *Emerg Med J* 2005;22:342-6.
131. Brindle R, Williams OM, Davies P et al. Adjunctive clindamycin for cellulitis: a clinical trial comparing flucloxacillin with or without clindamycin for the treatment of limb cellulitis. *BMJ Open* 2017;7:e013260.
132. Bruun T, Oppegaard O, Hufthammer KO, Langeland N, Skrede S. Early response in cellulitis: A prospective study of dynamics and predictors. *Clin Infect Dis* 2016;63:1034-41.
133. Gilchrist DM. A new approach to the National Outcomes Registry. National OPAT Conference, 2015 Apr 13; Business Design Centre, London. <http://bsac.org.uk/meetings/2015-national-opat-conference-2/>
134. Seaton RA, Sharp E, Bezlyak V, Weir CJ. Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections. *Int J Antimicrob Agents* 21;38:243-8.
135. Hepburn MJ, Dooley DP, Skidmore PJ et al. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. *Arch Intern Med* 2004;164:1669-74.
136. Thomas KS, Crook AM, Nunn AJ et al. Penicillin to prevent recurrent leg cellulitis. *N Engl J Med* 2013;368:1695-703.126.